Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally active, direct-acting P2Y12 receptor antagonist. It is reversible and does not require metabolic activation.
## Primary Indications
* Reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI) treated with aspirin.
## Adult Dosing
* **Acute Coronary Syndrome (ACS):**
* Loading Dose: 180 mg orally once.
* Maintenance Dose: 90 mg orally twice daily.
* **Post-Myocardial Infarction (MI) with history of ACS:**
* Maintenance Dose: 60 mg orally twice daily (initiated after at least 12 months of treatment with 90 mg twice daily, or earlier if clinically indicated, and continued for a total of at least 24 months from the initial ACS event).
Duration of therapy should be individualized. For patients with ACS, treatment is typically continued for at least 12 months.
## Pediatric Dosing
* There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is needed in patients with mild to moderate hepatic impairment. Ticagrelor is not recommended in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is needed in patients with mild, moderate, or severe renal impairment.
## Contraindications
* Active pathological bleeding.
* History of intracerebral hemorrhage.
* Hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Common:** Bleeding (major or minor, particularly at access sites), dyspnea, bradycardia, rash.
* **Serious:** Life-threatening bleeding, ventricular pauses.
* **Other:** Hyperuricemia, creatinine elevation.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor plasma concentrations. Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor plasma concentrations.
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concurrent use with CYP3A4 substrates with a narrow therapeutic index (e.g., simvastatin, atorvastatin) may increase the exposure to these substrates. Consider lower doses of statins.
* **Aspirin:** Combination therapy is indicated for ACS and post-MI patients. However, the risk of bleeding is increased.
* **Other Antiplatelets/Anticoagulants:** Concurrent use increases the risk of bleeding.
* **Morphine and Opioids:** May delay absorption of ticagrelor. If concomitant use is necessary, consider a potential interaction with P2Y12 inhibition.
* **Digoxin:** Ticagrelor can increase digoxin plasma concentrations; monitor digoxin levels and adjust dose as needed.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding.
* **Renal Function:** Monitor serum creatinine.
* **Uric Acid:** Monitor serum uric acid levels.
* **Bradycardia:** Assess heart rate, especially in patients with risk factors for bradycardia.
* **Digoxin Levels:** If co-administered, monitor digoxin levels.
## Clinical Pearls
* Ticagrelor is given twice daily, unlike clopidogrel (once daily) and prasugrel (once daily).
* Dyspnea is a common side effect and often transient. If severe, consider alternative antiplatelet therapy.
* Discontinuation of ticagrelor prematurely increases the risk of stent thrombosis, MI, and death.
* For patients undergoing PCI who require oral anticoagulation, ticagrelor should generally be avoided.
***
*Disclaimer: This information is intended for clinical pharmacists and should not replace a thorough review of the current prescribing information and clinical literature. Always verify current product labeling and institutional protocols.*
